# Maximakinin : An Amphibian Bradykinin Homologue and Selective B2 Receptor Agonist
> **Research Use Only (
References
- •PMID: 33707758
- •PMID: 29414245
- •
- •
- •
RUO).** Maximakinin and related kinin peptides are described here strictly as laboratory research reagents for in-vitro and biochemical study. Nothing below is a human, veterinary, clinical, diagnostic, or therapeutic claim, and no dosing guidance is implied. Handle as a research chemical under appropriate institutional safety practices.
Maximakinin is a naturally occurring extended homologue of bradykinin, isolated from the skin secretion and venom of the Chinese red-belly toad Bombina maxima. Where mammalian bradykinin is a nine-residue vasoactive nonapeptide, maximakinin is a nonadecapeptide — a 19-residue peptide whose C-terminus reproduces the canonical bradykinin sequence (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) while carrying an additional N-terminal decapeptide extension. That extension is what makes maximakinin a distinctive research reagent: it preserves bradykinin-like receptor activity while altering potency, selectivity, and receptor-trafficking behavior.
Discovery and molecular origin
Maximakinin was first characterized as a novel bradykinin-related peptide (BRP) recovered from Bombina maxima skin secretions, together with its biosynthetic precursor Biochem Biophys Res Commun, 2001. Subsequent molecular work cloned the maximakinin precursor cDNAs from Bombina maxima venom, establishing that the peptide is encoded as part of a larger preprotein and liberated by proteolytic processing — a pattern shared with many amphibian skin host-defense and bioactive peptides Peptides, 2003. Amphibian skin is an exceptionally rich source of kinin-like sequences, and maximakinin is among the most studied of the Bombina BRPs.
Structure–activity: an extended bradykinin
The defining structural feature of maximakinin is the N-terminal extension appended to an intact bradykinin C-terminus. Because the C-terminal nonapeptide is the principal determinant of kallikrein–kinin receptor engagement, maximakinin retains agonist activity at the bradykinin B2 receptor. The added N-terminal residues, however, modify the peptide's pharmacology in ways that have made it a useful probe.
Classic smooth-muscle pharmacology characterized maximakinin as a receptor-selective, bradykinin-related nonadecapeptide with a defined activity profile on isolated tissue preparations Regul Pept, 2004. Comparative work later demonstrated species-specific pharmacology: maximakinin's potency and selectivity differ across receptor orthologues, making it a tool for dissecting how subtle receptor sequence differences shape kinin responses PeerJ, 2017.
The relationship between the two peptides is easiest to read as a side-by-side comparison, which also clarifies why maximakinin is treated as a complement to bradykinin in research panels rather than a simple substitute:
| Property | Bradykinin | Maximakinin |
|---|---|---|
| Length | 9 residues (nonapeptide) | 19 residues (nonadecapeptide) |
| Source | Mammalian kallikrein–kinin system | Bombina maxima skin/venom |
| Core pharmacophore | C-terminal nonapeptide | Same C-terminal nonapeptide |
| Distinctive feature | Native ligand | N-terminal decapeptide extension |
| B2 signalling | Rapid, transient | Prolonged, altered trafficking |
| Cross-species potency | Reference | Species-selective |
Because both peptides share the receptor-engaging C-terminus, differences in their behavior can be attributed largely to the N-terminal extension — a clean structure–activity comparison that is difficult to set up with unrelated ligands.
Context within the kallikrein–kinin system
In mammals, bradykinin is generated when kallikreins cleave kininogen precursors, and it signals chiefly through the constitutively expressed B2 receptor (with the inducible B1 receptor becoming relevant under inflammatory conditions). The downstream consequences — vasodilation, increased vascular permeability, and sensitization of sensory neurons — are central to inflammation and pain biology. Maximakinin lets researchers interrogate this same B2 receptor with a structurally extended agonist, probing how the receptor responds to a ligand that nature optimized in a very different organism. That comparative leverage is why amphibian kinins are valued as pharmacological tools rather than mere curiosities, and it connects maximakinin to the wider family of vasoactive cardiovascular peptides studied in the lab.
Receptor signalling and trafficking
A particularly informative property of maximakinin is its effect on B2 receptor signalling dynamics. Stimulation of the bradykinin B2 receptor with this amphibian peptide produces prolonged signalling and altered receptor trafficking relative to bradykinin itself Pharmacol Res, 2012. For researchers studying GPCR desensitization, internalization, and recycling, maximakinin therefore serves as a pharmacological tool that decouples receptor activation kinetics from the native ligand — a useful contrast when mapping the vasoactive peptide signalling landscape.
This trafficking behavior also makes maximakinin attractive as a scaffold for engineered constructs. Fluorescent-protein fusions in which GFP is appended to peptide agonists, including maximakinin, have been used to visualize agonist–receptor interactions at dissimilar GPCRs Pharmacol Res Perspect, 2013. Bifunctional fusion proteins built around the maximakinin sequence extend this idea, combining the kinin pharmacophore with additional functional domains for research applications Can J Physiol Pharmacol, 2018.
Reported vascular and cardiac activity in research models
Recent in-vitro and animal-model studies have examined maximakinin's effects on the cardiovascular system, situating it alongside the broader renin–angiotensin and ACE2–Mas axes as a vasoactive research peptide:
- •Vascular smooth muscle calcium handling: maximakinin was reported to reduce intracellular Ca²⁺ levels in vascular smooth muscle cells through an AMPK/ERK-dependent pathway Hypertens Res, 2023.
- •Blood-pressure models: an antihypertensive effect of maximakinin was described in spontaneously hypertensive rats, attributed to AMPK/Akt/eNOS signalling Hypertens Res, 2021.
- •Cardiac oxidative stress: maximakinin reversed H₂O₂-induced oxidative damage in rat cardiac H9c2 cells via AMPK-linked mechanisms Biomed Pharmacother, 2024.
These are research findings in defined cell and animal systems and are reported here only to characterize the reagent's documented experimental behavior — not as functional, therapeutic, or safety claims.
Why maximakinin is a useful research reagent
For investigators working on the kallikrein–kinin system and B2 receptor pharmacology, maximakinin offers several distinctive handles:
1. Extended-agonist architecture. The N-terminal extension on an intact bradykinin core lets researchers probe how flanking sequence modulates receptor kinetics.
2. Altered trafficking phenotype. Prolonged signalling and modified internalization make it a contrast tool to native bradykinin Pharmacol Res, 2012.
3. Species-selective pharmacology. Differential potency across orthologues supports comparative receptor studies PeerJ, 2017.
4. Fusion-compatible scaffold. Demonstrated GFP and bifunctional fusions enable imaging and multi-domain construct design Pharmacol Res Perspect, 2013 Can J Physiol Pharmacol, 2018.
It sits naturally in a comparative panel alongside other vasoactive and cardiovascular research peptides.
Handling and reconstitution notes
Synthetic maximakinin supplied for research is typically lyophilized. Standard peptide practice applies: review the certificate of analysis for identity and purity, confirm purity by HPLC and mass spectrometry, and select an appropriate vehicle following a solubility guide. As a relatively hydrophilic kinin, maximakinin is generally water-soluble, but reconstitution should still be documented carefully per standard reconstitution practice. When sourcing material, ordinary supplier-evaluation diligence applies.
Summary
Maximakinin is a 19-residue bradykinin-related peptide from Bombina maxima that pairs an intact bradykinin C-terminus with an N-terminal extension. It acts as a B2 receptor agonist with species-selective pharmacology and a distinctive prolonged-signalling, altered-trafficking phenotype, and it has been engineered into fluorescent and bifunctional fusion constructs. With recent reports of AMPK-linked vascular and cardiac activity in research models, maximakinin is a mechanistically rich reagent for kallikrein–kinin and GPCR-trafficking research.
Kallikrein-kinin system context
Maximakinin functions within the broader kallikrein-kinin system (KKS), a proteolytic cascade that generates vasoactive kinins from kininogen precursors via tissue and plasma kallikreins. In mammals, the principal products are bradykinin (B2 receptor agonist) and des-Arg⁹-bradykinin (B1 receptor agonist). Maximakinin, as an amphibian non-KKS member with bradykinin-like activity, provides a species-orthogonal ligand for studying B2 receptor biology independently of the endogenous mammalian KKS.
This is particularly useful in experiments where endogenous kinins cannot be fully suppressed — for example, in models where plasmin or tissue kallikrein activity complicates pharmacological inhibition of the KKS. Because maximakinin is not a product of mammalian KKS enzymes, it cannot be generated de novo in mammalian tissue preparations, eliminating the confound of ongoing endogenous kinin production that can complicate BK-based assay designs.
Key KKS components for experimental context:
| Component | Role | Relevance to maximakinin research |
|---|---|---|
| High-MW kininogen (HMWK) | Precursor for plasma BK | Not relevant (maximakinin is not a HMWK product) |
| Tissue kallikrein | Generates Lys-BK from low-MW kininogen | Not a maximakinin precursor |
| ACE (kininase II) | Cleaves C-terminal His-Leu from BK → inactive | ACE acts on maximakinin's bradykinin C-terminus similarly; half-life extended by N-terminal extension |
| NEP (kininase I/neprilysin) | Cleaves at multiple sites | Maximakinin's N-terminal extension adds cleavage sites; metabolic profiling recommended |
| B2 receptor | Principal BK receptor; constitutive expression | Maximakinin's primary target; use B2 antagonists (HOE-140/icatibant) for specificity confirmation |
| B1 receptor | Upregulated in inflammation; des-Arg⁹-BK agonist | Maximakinin shows low B1 activity; useful as a B2-selective tool versus des-Arg⁹-BK |
B2 receptor pharmacology and receptor trafficking comparisons
B2 receptors (B2R) are prototypical peptide GPCRs coupled to Gq/11, Gi, and Gs depending on cell type and agonist. Maximakinin's prolonged signaling and altered internalization phenotype (relative to BK) make it a useful comparator for studies investigating B2R trafficking, biased agonism, and receptor desensitization.
Trafficking differences between BK and maximakinin at hB2R:
In HEK-293 cells stably expressing hB2R-GFP, time-lapse confocal imaging reveals:
- •BK: rapid receptor clustering and internalization (~5 minutes post-stimulation) via clathrin-coated pits; receptor recycling to the plasma membrane within 30–60 minutes
- •Maximakinin: slower initial internalization rate (~15 minutes for equivalent cluster density), but more sustained intracellular signaling from endosomal compartments — consistent with prolonged ERK1/2 phosphorylation measured by immunoblot at the 30–60 minute timepoints
These differences, first reported in 2012 Pharmacol Res, 2012, have since been used to probe the hypothesis that prolonged endosomal GPCR signaling contributes to the duration of biological effects — a concept now central to GPCR drug discovery. Maximakinin serves as a naturally occurring "biased agonist" model at B2R for trafficking-focused studies.
AMPK pathway and vascular/cardiac research applications
Maximakinin's documented cardiovascular effects include vasodilation and cardiac-protective actions in rodent models, and recent work has implicated AMP-activated protein kinase (AMPK) as a downstream mediator:
- •In isolated rat aortic rings, maximakinin-evoked vasodilation involves eNOS phosphorylation at Ser-1177 (a known AMPK substrate), and is partially blocked by the AMPK inhibitor compound C
- •In cardiomyocyte models subjected to simulated ischemia-reperfusion injury, maximakinin pre-treatment reduced LDH release and preserved mitochondrial membrane potential in an AMPK-dependent manner — effects not replicated by bradykinin at equimolar concentrations
These AMPK-linked cardiac findings position maximakinin as a research tool for studies at the intersection of GPCR signaling and metabolic regulation — a growing area connecting kinin biology to cardioprotection, energy sensing, and insulin sensitization pathways.
Fusion protein and imaging applications
Maximakinin's unique N-terminal extension has been used as a scaffold for fluorescent protein and bifunctional fusion constructs:
GFP-maximakinin: Recombinant GFP fused to the N-terminus of maximakinin retains B2R agonist activity (albeit with modestly reduced potency), enabling real-time receptor tracking in live cells. The construct helped establish that the N-terminal extension is highly tolerant of steric bulk — a property useful for researchers designing tagged agonists for imaging applications Pharmacol Res Perspect, 2013.
Bifunctional fusions: Constructs joining maximakinin to enzyme substrates or second-messenger binding domains have been explored as biosensor components — where the kinin portion drives B2R-mediated cell signaling and the fusion partner reports the downstream second-messenger response in real time.
These fusion-tolerant properties make maximakinin a more versatile scaffold than native BK for researchers designing novel molecular tools that require maintained B2R agonism alongside an N-terminal functional module.
In vitro assay considerations
Ca²⁺ mobilization assay: In B2R-expressing CHO or HEK cells, maximakinin evokes Gq/PLCβ-driven Ca²⁺ transients with EC₅₀ values of 1–10 nM (comparable to bradykinin). The key experimental difference: maximakinin produces longer-duration Ca²⁺ oscillations at subsaturating concentrations — important in Ca²⁺-imaging experiments to distinguish maximakinin from BK by kinetics rather than only by peak amplitude.
Aortic ring contractility (relaxation): Rat aortic rings pre-contracted with phenylephrine relax dose-dependently to maximakinin (1 nM – 1 µM) in an endothelium-dependent manner. Use HOE-140 (icatibant) as the B2R antagonist control; L-NAME (NO synthase inhibitor) partially inhibits the response, confirming eNOS involvement. Maximakinin's longer-duration relaxation response (relative to BK) is a practical advantage in slow-kinetics assays.
ERK phosphorylation time-course: Because of the prolonged endosomal signaling phenotype, maximakinin-stimulated ERK phosphorylation shows a characteristic biphasic profile — an early peak at 5–10 minutes (plasma membrane origin) and a sustained second peak at 30–60 minutes (endosomal origin). Sampling at a single 10-minute timepoint, as in standard BK assays, will miss the endosomal component. Plan ERK time-courses with samples at 5, 15, 30, 60, and 90 minutes when characterizing maximakinin responses.
---
This article is provided for informational and research purposes only. Peptides and related compounds described here are research-use-only (RUO) laboratory reagents and are not intended for human or veterinary diagnostic, therapeutic, or other use. No statement herein constitutes medical advice or a claim of safety or efficacy.